Celsion is now funding branded oncology drug development through a fastest-path-to-commercialization strategy for ThermoDox®, its proprietary thermally sensitive liposomal encapsulation of doxorubicin. We are also identifying opportunities to expand our range of therapeutic indications through investments in our core technology platform.
To maximize global commercialization following approval, Celsion is developing distribution alliance opportunities for ThermoDox in key geographic markets. Once these are finalized we will seek to acquire additional platform technology and chemotherapeutic candidates to add to our development pipeline.
Celsion will continue to strengthen its prospects for the future through its research, license and commercialization agreements with leading institutions, among others; the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic and the North Shore Long Island Jewish Health System.
http://celsion.com/ Low Temperature Sensitive Liposome -
LTSL Video of this technology in action:
http://origin-qps.onstreammedia.com/origin/shareholder/Archive/wmdemand/hostedfiles/30924CLN_MOA.wmv 
CHART:
